Last reviewed · How we verify

TAS6417 — Competitive Intelligence Brief

TAS6417 (TAS6417) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TGF-β receptor inhibitor. Area: Oncology.

phase 3 TGF-β receptor inhibitor ALK5 (activin receptor-like kinase 5) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TAS6417 (TAS6417) — Taiho Oncology, Inc.. TAS6417 is a small-molecule inhibitor of TGF-β signaling that blocks the TGF-β receptor pathway to reduce immunosuppression in the tumor microenvironment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TAS6417 TARGET TAS6417 Taiho Oncology, Inc. phase 3 TGF-β receptor inhibitor ALK5 (activin receptor-like kinase 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TGF-β receptor inhibitor class)

  1. Nuvation Bio Inc. · 1 drug in this class
  2. Ocuphire Pharma, Inc. · 1 drug in this class
  3. Taiho Oncology, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAS6417 — Competitive Intelligence Brief. https://druglandscape.com/ci/tas6417. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: